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Abstract: Background: The use of recombinant activated factor VII
(rFVIIa) on an off-label basis to treat life-threatening bleeding has
been associated with a perceived increased risk of thromboembolic
complications. However, data from placebo-controlled trials are
needed to properly assess the thromboembolic risk. To address this
issue, we evaluated the rate of thromboembolic events in all pub-
lished randomized, placebo-controlled trials of rFVIIa used on an
off-label basis.
Methods:We analysed data from 35 randomized clinical trials (26
studies involving patients and nine studies involving healthy volun-
teers) to determine the frequency of thromboembolic events. The
data were pooled with the use of random-effects models to calculate
the odds ratios and 95% conﬁdence intervals.
Results: Among 4468 subjects (4119 patients and 349 healthy vol-
unteers), 498 had thromboembolic events (11.1%). Rates of arterial
thromboembolic events among all 4468 subjects were higher among
those who received rFVIIa than among those who received placebo
(5.5% vs. 3.2%, P = 0.003). Rates of venous thromboembolic events
were similar among subjects who received rFVIIa and those who
received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa,
2.9% had coronary arterial thromboembolic events, as compared
with 1.1% of those who received placebo (P = 0.002). Rates of arterial
thromboembolic events were higher among subjects who received
rFVIIa than among subjects who received placebo, particularlyJournal of Hepatology 20
Keywords: Cirrhosis; Variceal bleeding; rFVIIa.
Received 21 December 2010; received in revised form 14 January 2011; accepted 16
January 2011
⇑Corresponding author. Address: Université Pierre et Marie Curie, Service
d’hépato-gastroentérologie, Hôpital de la Pitié-Salpêtrière (AP-HP), 47-83 bd de
l’hôpital, 75013 Paris, France. Tel.: +33 1 42 16 14 54; fax: +33 1 42 16 14 25.
E-mail address: dominique.thabut@psl.aphp.fr (D. Thabut).
Abbreviations: rFVIIa, recombinant activated coagulation factor; OLT, orthotopic
liver transplantation; Ht, haematocrit; UGIB, upper gastro-intestinal bleeding;
PVT, portal vein thrombosis; RBC, red blood cells.P = 0.003); the rates were especially high among subjects 75 years
of age or older (10.8% vs. 4.1%, P = 0.02).
Conclusions: In a large and comprehensive cohort of persons in pla-
cebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa
on an off-label basis signiﬁcantly increased the risk of arterial but
not venous thromboembolic events, especially among the elderly.
(Funded by Novo Nordisk.).
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Recombinant activated coagulation factor (rFVIIa – Novoseven,
Novo Nordisk) is indicated for the prevention and treatment of
A and B haemophilia-related bleeding. The efﬁcacy of rFVIIa has
been recently tested in patients with other clinical conditions
including patients’ central nervous system bleeding, trauma, car-
diac surgery, spinal surgery, and liver disease with various efﬁca-
cies. Because of the particular coagulation proﬁle of patients with
chronic liver diseases, a lot of studies were performed in cirrhotic
patients or patients undergoing hepatic surgery. To date, seven
studies were reported in this setting [1–7]. Six of them are
detailed in Table 1 [1–6]. All those studies were negative as far
as the primary endpoint was concerned. However: (1) in one
study performed in patients with severe liver disease who were
bleeding from oesophageal varices, treatment with rFVIIa was
associated with a gain in survival [1]; (2) in three studies, either
the number of patients transfused or the loss of haematocrit (Ht)
or the number of patients reaching primary endpoint in post hoc
analyses was signiﬁcantly improved in rFVIIa group [2–4]. If this
is far from enough to expect the approval for rFVIIa use in vari-
ceal bleeding, hepatectomy, or OLT, it allows us to think that this
medicine could be used off-label in some particular subsets of
patients with severe uncontrolled bleeding. Here, the issue of
avoiding harm is crucial, since one will never get the proof that
the prescription of this pro-coagulant factor was mandatory.
The primary concern surrounding the use of rFVIIa is the
occurrence of thromboembolic events. In the November 4 issue
of the NEJM, Levi et al. evaluated the rate of thromboembolic
events in all randomised placebo-controlled trials of rFVIIa used
on an off-label basis [8]. The authors found 35 randomized con-
trolled trials involving 4468 subjects. Of them, 498 had thrombo-
embolic events (11.1%). Although the rates did not statistically11 vol. 55 j 483–485
Table 1. Design, efﬁcacy, and safety of rFVIIa in the six liver-related studies published as full-text articles.⁄
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⁄Another study, only published as an abstract, will not be described here because of the lack of data available [7].
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differ when both arterial and venous events were taken into
account (10.2% vs. 8.7%; [0.94–1.47]; p = 0.16), rates of arterial
events were higher in the treatment group (5.5% vs. 3.2%,
OR = 1.68 [1.20–2.36]; p = 0.003). The odds ratio for arterial
thromboembolic events reached 2.39 [1.39–4.09] for coronary
events, and patients aged more than 65 years old carried the
highest risk of developing a thromboembolic complication with
the treatment (OR = 2.43 [1.34–4.41]). This meta-analysis
included all the studies displayed in Table 1. When the analysis
was restricted to patients with advanced liver disease, although
more arterial thromboembolic events were found in the rFVIIa
treatment group than in the placebo group, the statistical signif-
icance was not reached (OR = 2.19 [0.89–5.42]; p = 0.09).
The study by Levi et al. provides interesting insights in the
potential complications of this treatment. However, it suffers
from several limitations that alter the soundness of its conclu-
sions. First, the evidence comes from many studies of low sample
size that were heterogeneous in baseline risk for thromboembolic
events and regimen of administration. Second, thromboembolic
events were not routinely sought for in all the studies. Moreover,
the statistical approach is unclear: we were unable to determine
whether the authors had access to the individual patients’ data or
only published data and whether the centre effect was taken into
account. This point is especially relevant since incorrect pooling
of data may lead to erroneous conclusions. Lastly, the type II error
is increased due to multiple testing and as such may lead to a
higher risk of ﬁnding signiﬁcant results by chance only; this is
a limitation that applies to meta-analyses in general.
The results of this study must be analysed in the light of the
potential beneﬁts of rFVIIa treatment in our patients with
advanced liver disease. The risk of thrombolic events in the set-
ting of liver disease is a major issue, since coagulation disorders
may affect the procoagulant as well as the anticoagulant capaci-
ties [9]. Moreover, some authors even claim cirrhosis is a proco-
agulant disease, and that decompensations are favoured by an
imbalance towards increased coagulation. Therefore, one must
be particularly cautious when using procoagulant drugs in this
setting. However, all things considered, rFVIIa is unlikely to be
used routinely in liver patients; therefore, the balance between
risk and beneﬁt should guide our decisions as long as this drug
is available for off-label use in some countries. If we restrict the
use of rFVIIa to uncontrolled bleeding, occurring in less than
10% of patients with variceal bleeding [10], hepatectomy, and
OLT, the risk of myocardial infarction or cerebrovascular events,
that are the most common arterial thromboembolic events
observed when using rFVIIa in liver patients (see Table 1), andJournal of Hepatology 201the fear of hepatic arterial thrombosis during OLT could be
considered as collateral damages which occur when performing
a salvage therapy. Hence, the potentially increased risk of arterial
thromboembolic events in patients with advanced liver disease
should be balanced with its beneﬁts in select-few patients with
uncontrolled bleeding.Conﬂict of interest
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